Arca
Skip to content
Tools
Tools

SELP: P-selectin

Ca(2+)-dependent receptor for myeloid cells that binds to carbohydrates on neutrophils and monocytes.

  • Drugs that act on it: 4
  • Approved: 1
  • In phases 1 to 3: 3
  • Sponsors: 3

Who is on it, and how far along

Every drug ChEMBL records acting on SELP, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 1
  • Antibody 2
  • Other 1

Approved1

  • Crizanlizumab

Phase 32

  • Inclacumab
  • Rivipansel

Phase 21

  • RG-1512

Phase 10

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    • GlycoMimetics Incorporated125%

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
    CrizanlizumabWithdrawnApprovedNovartis PharmaceuticalsAntibodyBlockerP-selectin blocker5
    InclacumabPhase 3RocheAntibodyAntagonistP-selectin antagonist0
    RivipanselPhase 3GlycoMimetics IncorporatedSmall moleculeAntagonistP-selectin antagonist0
    RG-1512Phase 2—OtherInhibitorP-selectin inhibitor0

    Open trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 5 in all, from ClinicalTrials.gov.

    Diseases most associated with it

    Open Targets association score, 0 to 1; all associations
    Deep vein thrombosis
    0.30
    Thrombophilia
    0.30
    Asthma
    0.29
    Aging
    0.29
    Premature coronary artery atherosclerosis
    0.26
    Abnormality of the skeletal system
    0.25
    Neoplasm
    0.12

    Genes and related targets

    Complexes and families that share a gene with this target
    Genes
    SELP
    Related
    Selectin

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL5378, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P16109, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

    Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.